Noom Inc., a startup that for years has touted a psychological path to weight loss, is now ready to add drugs to the equation.
After a pilot last year, the company is launching its Noom Med option that will include prescriptions for obesity drugs like Novo Nordisk A/S's Wegovy for about $120 a month. It's the latest weight-loss company to join the lifestyle-focused industry's push into using highly effective, costly GLP-1 obesity drugs to help customers slim down.
Noom is among a field of companies aiming to capitalize on the drugs that help people feel fuller and eat less with relatively few side effects. Patients who took the highest dose of Mounjaro, a diabetes drug from Eli Lilly & Co. that's in testing as an obesity treatment, lost an average of 50 pounds. Many one-time dieters see those results as far more reliable and easily obtained than from traditional habit-changing programs.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
